CONSORT diagram showing inclusion/exclusion criteria. A total of 922 patients who underwent allo-HCT at St Jude between 2000 and 2020 were eligible for analysis. Inclusion criteria encompassed having undergone their first allo-HCT, age < 21 years, use of bone marrow (BM) or peripheral blood stem cells (PBSCs) as the cell source, a primary diagnosis other than solid tumor, HLA match information available, and survival >30 days. A total of 738 eligible patients satisfied these criteria and remained in the study cohort.